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Background: 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) has been used to evaluate tumor malignancy and cell
proliferation in human brain gliomas. However, 18F-FLT has several limitations in clinical use. Recently, 11C-labeled
thymidine analogue, 4′-[methyl-11C]thiothymidine (11C-4DST), became available as an in vivo cell proliferation positron
emission tomography (PET) tracer. The present study was conducted to evaluate the usefulness of 11C-4DST PET in the
diagnosis of human brain gliomas by comparing with the images of 18F-FLT PET.
Methods: Twenty patients with primary and recurrent brain gliomas underwent 18F-FLT and 11C-4DST PET scans. The
uptake values in the tumors were evaluated using the maximum standardized uptake value (SUVmax), the tumor-to-normal
tissue uptake (T/N) ratio, and the tumor-to-blood uptake (T/B) ratio. These values were compared among different glioma
grades. Correlation between the Ki-67 labeling index and the uptake values of 11C-4DST and 18F-FLT in the
tumor was evaluated using linear regression analysis. The relationship between the individual 18F-FLT and 11C-4DST
uptake values in the tumors was also examined.
Results: 11C-4DST uptake was significantly higher than that of 18F-FLT in the normal brain. The uptake values of 11C-4DST
in the tumor were similar to those of 18F-FLT resulting in better visualization with 18F-FLT. No significant differences in
the uptake values of 18F-FLT and 11C-4DST were noted among different glioma grades. Linear regression analysis showed
a significant correlation between the Ki-67 labeling index and the T/N ratio of 11C-4DST (r = 0.50, P < 0.05) and 18F-FLT
(r = 0.50, P < 0.05). Significant correlations were also found between the Ki-67 labeling index and the T/B ratio of 11C-4DST
(r= 0.52, P < 0.05) and 18F-FLT (r= 0.55, P< 0.05). A highly significant correlation was observed between the individual
T/N ratio of 11C-4DST and 18F-FLT in the tumor (r = 0.79, P = 0.0001).
Conclusions: The present study demonstrates that 11C-4DST is useful for the imaging of human brain gliomas
with PET. A relatively higher background uptake of 11C-4DST in the normal brain compared to 18F-FLT limits the
detection of low-tracer-uptake tumors. Moreover, no superiority was found in 11C-4DST over 18F-FLT in the
evaluation of cell proliferation.
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Imaging of cell proliferation and DNA synthesis is an at-
tractive target for diagnosing and treating tumors. A fluori-
nated thymidine analogue, 3′-deoxy-3′-[18F]fluorothymidine
(18F-FLT) (Figure 1A), has emerged as a promising positron
emission tomography (PET) tracer for evaluating cell
proliferation in various malignant brain tumors [1-4].
Fluorothymidine (FLT) is phosphorylated by thymidine
kinase-1 (TK1) and trapped inside the cells. The appli-
cation of 18F-FLT as a marker of cell proliferation is
based on the assumption that cellular 18F-FLT trapping
is a representation of thymidine incorporation into DNA
[5,6]. However, previous studies including our recent re-
port have shown that the major portion of 18F-FLT uptake
is due to increased transport and influx through the dis-
rupted blood-brain barrier (BBB) but not increased phos-
phorylation process by TK1 [7,8]. Non-enhancing tumors
with an intact BBB have limited transport for the tracer,
and their cell proliferation cannot be adequately assessed
by 18F-FLT [4,9]. Moreover, little 18F-FLT is actually
incorporated into DNA synthesis; rather, it is retained
intracellularly after mono-phosphorylation by TK1 [10].
Therefore, 18F-FLT uptake in the tumor does not reflect
the whole DNA synthesis.
Recently, Toyohara et al. developed a new thymi-
dine analogue, 4′-[methyl-11C]thiothymidine (11C-4DST)
(Figure 1B), for cell proliferation PET-imaging tracer
[11,12]. 11C-4DST is resistant to degradation by thymi-
dine phosphorylase and incorporated into DNA synthesis
[12]. 11C-4DST showed high-tumor uptake (sensitivity) and
high-tumor selectivity in a rodent tumor model [13]. In a
pilot study in human brain tumors, 11C-4DST showed little
uptake in normal brain tissue, resulting in low-background
activity for imaging brain tumors [14]. 11C-4DST PETFigure 1 Radiopharmaceutical structures of 18F-FLT (A) and 11C-4DST
thiothymidine.demonstrated rapid uptake in aggressive tumor masses,
whereas no uptake of 11C-4DST was seen in clinically
stable disease [14]. 11C-4DST might be superior to 18F-FLT
in evaluating cell proliferation and treatment response and
predicting prognosis as 11C-4DST uptake represents the
whole DNA synthesis process. The difference of radio-
pharmaceutical structure between 11C-4DST and 18F-FLT
(Figure 1A,B) is small; however, it has been recognized
that small molecular changes of the chemical structure
sometimes make greater difference in the pharmacokinet-
ics of PET tracers. The differences of thymidine kinase se-
lectivity, nucleoside transporter subtype, and rate-limiting
step enzyme between 11C-4DST and 18F-FLT may change
the characterization of PET findings [15]. No comparison
has been reported between 11C-4DST and 18F-FLT for
in vivo imaging tool of tumors. In the present study, we
demonstrate our initial experience of 11C-4DST PET im-
aging and compare the images of 11C-4DST and 18F-FLT




Twenty primary (n = 9) and recurrent (n = 11) human
brain gliomas (9 men and 11 women; mean age, 52.9 ±
18.6 years; range, 22 to 79 years; median, 47 years) were
included in this study (Table 1). Histopathology was ex-
amined on tissue specimens obtained by biopsy (n = 3)
or resection (n = 17). Twelve patients had grade IV glioma
(10 glioblastoma, 2 glioblastoma with oligodendroglioma
component), 6 had grade III glioma (4 anaplastic astrocy-
toma, 2 anaplastic oligoastrocytoma), and 2 had grade II
diffuse astrocytoma. The cellular proliferation activity of
the tumor was determined by measuring the Ki-67(B). 18F-FLT, 3′-deoxy-3′-[18F]fluorothymidine; 11C-4DST, 4′-[methyl-11C]
Table 1 Patient characteristics and PET data





SUVmax T/N ratio SUVmax T/N ratio
1 64/F DA Primary 1 0.53 1.71 0.57 2.71
2 22/M DA Primary 5 0.53 1.51 0.28 1.75
3 46/M AA Primary 15 0.85 2.24 0.95 5.59
4 73/M AA Primary 20 2.35 6.91 2.41 14.18
5 64/M AOA Primary 85 1.13 3.77 1.06 7.57
6 69/F GBM Primary 20 1.63 4.66 1.34 6.70
7 39/F GBM Primary 70 1.44 4.80 1.72 7.82
8 76/F GBM Primary 90 6.95 18.29 3.23 17.95
9 72/F GBM-O Primary 70 1.57 4.76 1.35 7.11
10 34/M AA Recurrence 22 2.24 9.33 1.88 14.46
11 73/M AOA Recurrence 80 2.67 8.34 4.68 20.35
12 47/F AOA Recurrence 35 1.52 4.34 1.78 7.74
13 52/M GBM Recurrence 15 2.80 6.09 2.56 15.06
14 46/M GBM Recurrence 35 3.50 10.94 3.52 15.30
15 29/F GBM Recurrence 50 1.56 6.50 1.52 13.82
16 46/M GBM Recurrence 70 3.11 8.64 3.12 18.35
17 29/F GBM Recurrence 60 1.22 4.69 1.95 13.93
16 79/F GBM Recurrence 40 1.90 4.63 1.94 7.46
19 69/M GBM Recurrence 5 1.52 4.47 1.45 8.06
20 29/F GBM-O Recurrence 20 1.10 2.50 1.38 5.11
aDA: diffuse astrocytoma, AA: anaplastic astrocytoma, AOA: anaplastic oligoastrocytoma, GBM: glioblastoma, GBM-O: glioblastoma with oligodendroglioma component.
4DST: 4′-thiothymidine, FLT: fluorothymidine, SUVmax: maximum standardized uptake value, T/N ratio: tumor-to-normal tissue uptake ratio.
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with anti-Ki-67 antibody (1:50, Dako, Glostrup, Denmark).
The percentage of tumor cells that stained positively for
Ki-67 antigen was measured in the area containing the
largest number of positive cells and was regarded as
representative of the tumor proliferative activity. PET
studies with 11C-4DST and 18F-FLT were performed
within 1 week before the surgery. The two PET studies
could be performed on the same day; however, we per-
formed the examinations on two different days to de-
crease a physical burden on the patients because some
of the patients were ill and the mean interval between
the two examinations was 2.9 ± 1.7 days (median, 2 days).
All patients underwent routine magnetic resonance im-
aging (MRI) examination including contrast-enhanced
T1-weighted MRI. The use of 11C-4DST and 18F-FLT
as a PET tracer was approved by Kagawa University,
Faculty of Medicine Human Subjects Ethical Committees
and informed consent was obtained from all patients
before PET examination.
11C-4DST and 18F-FLT synthesis and PET acquisition
11C-4DST was synthesized according to the method de-
scribed by Toyohara et al. [14], and the radiochemical
purity of 11C-4DST was >95%. 18F-FLT was synthesizedaccording to the method described by Martin et al. [16],
and the radiochemical purity of 18F-FLT was >95%. All
chemical reagents for tracer synthesis were purchased
from commercial sources. PET examination was per-
formed using a Biograph mCT64 PET/CT scanner
(Siemens/CTI, Knoxville, TN, USA). The image systems
enabled simultaneous acquisition of 74 transverses per
field of view (FOV), with an intersection spacing of 3 mm,
for a total axial FOV of 21.6 cm. The in-plane transverse-
reconstructed resolution was 4.3 mm full width at half
maximum (FWHM) in the brain FOV. No special dietary
instructions were given to the patients before PET exam-
ination. Images were acquired with patients in the supine
position, resting, with their eyes closed. CT data were ac-
quired first (tube rotation time 0.6 s per revolution,
120 kV, 192 mAs, reconstructed slice thickness of 3 mm)
and used for attenuation correction and anatomical
localization of the tumors. For the 11C-4DST study, a dose
of 229 to 587 MBq (mean, 391 ± 108 MBq) of 11C-4DST
was injected intravenously, and regional emission im-
ages were obtained for 15 min, beginning 15 min after
the 11C-4DST administration. For the 18F-FLT study, a
dose of 237 to 342 MBq (mean, 309 ± 24 MBq) of 18F-FLT
was injected intravenously, and regional emission im-
ages were obtained for 15 min, beginning 60 min after
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performed using ordered subset expectation maximization
(OSEM) with time of flight (TOF) and point spread function
(PSF). The reconstruction parameters were 2 iterations and
21 subsets. The FWHM of the Gaussian filter was 3 mm.
Data analysis
11C-4DST and 18F-FLT uptakes were semiquantitatively
assessed by evaluating the standardized uptake value
(SUV). A region of interest (ROI) was set manually by
an observer (N.K.) around the hottest area of each le-
sion or the area of tumor biopsy. The maximum value
of SUV (SUVmax) of the ROI was regarded as the
representative value of each tumor. To calculate the
tumor-to-normal tissue uptake (T/N) ratio and the tumor-
to-blood uptake (T/B) ratio, ROIs were set on the normal
brain parenchyma (usually contralateral normal cerebral
tissue excluding ventricles) and the vertical portion of
the superior sagittal sinus with the aid of PET/CT fu-
sion images. The mean values of SUV (SUVmean) of
the ROIs were calculated. The T/N and T/B ratios
were determined by dividing the SUVmax of the tumor
with the SUVmean of the normal brain and the super-
ior sagittal sinus.Figure 2 Gd-enhanced T1-weighted MRI, 11C-4DST PET, and 18F-FLT P
glioblastoma (Case 8). Gd-enhanced T1-weighted MR image demonstrates
lobe. PET studies with 11C-4DST and 18F-FLT PET show almost identical t
than 18F-FLT PET. (B) A 29-year-old woman with recurrent glioblastoma w
MR image demonstrates multiple spotty enhancements in the right temporo
visualized with 11C-4DST but well visualized with 18F-FLT. 18F-FLT, 3′-deoStatistical analysis
All parametric data were expressed as mean ± SD. Paired
Student t-test was used to compare the individual uptake
values of 11C-4DST and 18F-FLT in the normal brain and
tumor. Differences in the uptake values of 11C-4DST
and 18F-FLT among different glioma grades were com-
pared using analysis of variance. Linear regression ana-
lysis was used to evaluate the relationship between the
uptake values of 11C-4DST and 18F-FLT and the Ki-67
labeling index of the tumor. The relationship between
the individual 11C-4DST and 18F-FLT uptake in the
tumor was also examined by linear regression analysis.
Differences were considered statistically significant at a
P value of less than 0.05.
Results
Visual assessment
Both 11C-4DST and 18F-FLT showed little uptake in the
normal brain, and 11C-4DST uptake was visually higher
than 18F-FLT in almost all cases. 11C-4DST showed a high
uptake in the choroid plexus, whereas 18F-FLT showed a
faint uptake. 11C-4DST and 18F-FLT provided identical
PET images of the tumor in many cases (Figure 2A). Two
primary diffuse astrocytomas that had no contrastET of two patients. (A) A 76-year-old woman with newly diagnosed
a round lesion with irregular ring enhancement in the right frontal
racer uptake in the tumor. Background uptake of 11C-4DST is higher
ith oligodendroglioma component (Case 20). Gd-enhanced T1-weighted
-occipital lobes extending to the basal ganglia. The tumor is faintly
xy-3′-[18F]fluorothymidine; 11C-4DST, 4′-[methyl-11C]thiothymidine.
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with 11C-4DST. One of the two diffuse astrocytomas could
be visualized with 18F-FLT but the other could not. One re-
current glioblastoma with oligodendroglioma component
that had multiple spotty enhancements in contrast-
enhanced MRI was faintly visualized with 11C-4DST
but well visualized with 18F-FLT (Figure 2B). In total, 2
of 20 tumors were well visualized only in 18F-FLT PET.Semiquantitative analysis
In the normal brain, 11C-4DST uptake was significantly
higher than 18F-FLT (SUVmean; 0.34 ± 0.06 vs. 0.19 ±
0.04, P < 0.001 by paired t-test). Individual 11C-4DST
SUVmax in the tumor was almost comparable to 18F-FLT
except a few cases. Therefore, the average T/N ratio
of 18F-FLT in the tumor was significantly higher than
that of 11C-4DST (10.55 ± 5.45 vs. 5.96 ± 3.86, P < 0.001
by paired t-test) resulting in better tumor visualization
with 18F-FLT. The average 11C-4DST T/N ratio in WHOFigure 3 Linear regression analysis between the Ki-67 labeling index
correlation is observed between the Ki-67 labeling index in the tumor and
(B) A significant correlation is also observed between the Ki-67 labeling in
and 18F-FLT (r = 0.50, P < 0.05). (C) A significant correlation is also obse
ratio of 11C-4DST (r = 0.52, P < 0.05) and 18F-FLT (r = 0.55, P < 0.05). 18F-
thiothymidine; SUVmax, maximum standardized uptake value; T/N ratio
uptake ratio.grade II (n = 2), III (n = 6), and IV (n = 12) gliomas
was 1.16 ± 0.14, 5.82 ± 2.8, and 6.75 ± 4.25, respect-
ively. No significant differences of 11C-4DST T/N ra-
tio were observed among different glioma grades. The
average 18F-FLT T/N ratio in WHO grade II, III, and IV
gliomas was 2.23 ± 0.68, 11.65 ± 5.63, and 11.39 ± 4.78, re-
spectively. Again, no significant differences of 18F-FLT T/N
ratio were observed among different glioma grades.Correlation between Ki-67 index and uptake values
of 11C-4DST and 18F-FLT
Linear regression analysis showed a significant correlation
between the Ki-67 labeling index in the tumor and the
SUVmax of 11C-4DST (r = 0.46, P < 0.05) and 18F-FLT
(r = 0.49, P < 0.05) (Figure 3A). Moreover, a significant
correlation was observed between the Ki-67 labeling
index in the tumor and the T/N ratio of 11C-4DST (r =
0.50, P < 0.05) and 18F-FLT (r = 0.50, P < 0.05) (Figure 3B).
A significant correlation was also observed between theand the uptake values of 11C-4DST and 18F-FLT. (A) A significant
the SUVmax of 11C-4DST (r = 0.46, P < 0.05) and 18F-FLT (r = 0.49, P < 0.05).
dex in the tumor and the T/N ratio of 11C-4DST (r = 0.50, P < 0.05)
rved between the Ki-67 labeling index in the tumor and the T/B
FLT, 3′-deoxy-3′-[18F]fluorothymidine; 11C-4DST, 4′-[methyl-11C]
, tumor-to-normal tissue uptake ratio; T/B ratio, tumor-to-blood
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0.52, P < 0.05) and 18F-FLT (r = 0.55, P < 0.05) (Figure 3C).Correlation between individual 11C-4DST and 18F-FLT
uptake values
A highly significant correlation was observed between
the individual SUVmax of 11C-4DST and 18F-FLT in the
tumor (r = 0.71, P < 0.001) (Figure 4A). A highly signifi-
cant correlation was also observed between the individual
T/N ratio of 11C-4DST and 18F-FLT in the tumor (r = 0.79,
P = 0.0001) (Figure 4B).Discussion
In the present study, we demonstrate three important
findings in the comparison of imaging between 11C-4DST
and 18F-FLT for clinical application. Firstly, both tracers
had low-background activity in the normal brain and were
able to visualize the tumor well except one non-enhancing
primary diffuse astrocytoma in which both tracers failed
to visualize the tumor. Both tracers had similar uptake
values in the tumor, but the 18F-FLT uptake in the normal
brain was relatively lower than that of 11C-4DST, resulting
in better tumor visualization with 18F-FLT. Secondly, a sig-
nificant correlation was observed between the Ki-67 label-
ing index and the uptake values of 11C-4DST and 18F-FLT
in the tumor. We hypothesized that 11C-4DST is superior
to 18F-FLT in evaluating cell proliferation as 11C-4DST
uptake represents the whole DNA synthesis process.
However, the correlation coefficients of 11C-4DST uptake
values to the Ki-67 labeling index were slightly lower
than those of 18F-FLT. Finally, a strong correlation wasFigure 4 Linear regression analysis of the individual SUVmax (A) and
highly significant correlation is observed between the individual SUV max o
and 18F-FLT (r = 0.79, P < 0.0001). 18F-FLT, 3′-deoxy-3′-[18F]fluorothymidine; 1
standardized uptake value; T/N ratio, tumor-to-normal tissue uptake ratio.observed between the individual 11C-4DST and 18 F-FLT
uptake values in the tumor.
For oncological use, measurement of the cell prolifera-
tion and DNA synthesis is an attractive target for imaging.
A fluorinated thymidine analogue, 18F-FLT, has emerged
as a PET tracer for evaluating tumor-proliferating activity
in various brain tumors [1-4]. However, 18F-FLT has sev-
eral limitations in clinical use that have been reported in
previous studies [4,7-9]. Most critically, little 18F-FLT is
actually incorporated into DNA synthesis, and 18F-FLT
uptake in the tumor does not reflect the whole of DNA
synthesis [7,8,10]. With the drawbacks of 18F-FLT, efforts
were made to produce a more attractive PET tracer that
can be used to evaluate tumor malignancy and cell
proliferation accurately. Toyohara et al. focused on the
4′-thiothymidine (4DST) because of its metabolic sta-
bility and close similar structure to native thymidine
[11]. They synthesized 14C-labeled 4DST (14C-4DST)
as a model compound of 11C-labeled alternative and dem-
onstrated the evidence that 11C-4DST matches the concept
of the ideal DNA-synthesis-imaging agent [11]. Feasibility
studies of 11C-4DST in rodent tumor models showed
higher uptake than that of 18F-FLT and reflect the
DNA synthesis rate [12,13]. Usefulness of 11C-4DST
for the imaging of human brain tumors with PET was
investigated in a recent pilot study by comparing the
images of 11C-4DST and [11C]methionine (11C-MET)
in six patients with various brain tumors [14]. There
was little uptake of 11C-4DST in the normal brain and
rapidly growing brain tumors that were well visualized
in contrast-enhanced MRI and 11C-MET PET were
clearly seen in 11C-4DST PET. Although 11C-METT/N ratio (B) of the tumor between 11C-4DST and 18F-FLT. A
f 11C-4DST and 18F-FLT (r = 0.71, P < 0.001) and T/N ratio of 11C-4DST
1C-4DST, 4′-[methyl-11C]thiothymidine; SUVmax, maximum
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stable (non-aggressive) tumors with enhancement were
not detected with 11C-4DST. In addition, the distribu-
tion pattern of 11C-4DST in the tumor was not always
identical to that of 11C-MET. Here, we report the first
clinical study of comparing two nucleoside PET tracers
for DNA synthesis, 11C-4DST and 18F-FLT, for in vivo im-
aging of human brain gliomas. 11C-4DST PET images
were acquired for 15 min, beginning 15 min after the ad-
ministration. The start time for imaging 11C-4DST was
earlier than that for 18F-FLT PET imaging (60 min). We
confirmed that 11C-4DST uptake and distribution in the
tumor was almost fixed 15 min after 11C-4DST adminis-
tration in a preliminary dynamic acquisition study. Two
non-enhanced diffuse astrocytomas could not be visual-
ized with 11C-4DST suggesting that 11C-4DST does not
readily cross the intact BBB, and 11C-4DST uptake in the
tumor rather depends on the influx through the disrupted
BBB similar to 18F-FLT. The distribution pattern and up-
take value of 11C-4DST in the tumor are almost identical
to those of 18F-FLT except one non-enhanced primary dif-
fuse astrocytoma and one recurrent glioblastoma with
oligodendroglioma component in which only 18F-FLT
could detect the tumor well, whereas 11C-4DST showed no
and a faint uptake in the tumors, respectively. 11C-4DST
uptake in the normal brain was visually and semiquan-
titatively higher than 18F-FLT. A previous clinical study
reported that 11C-4DST is mainly metabolized by glucuro-
nidation in the human body and largely accumulated in
the liver [14]. Other metabolites could be nonspecifically
accumulated in the normal brain. Furthermore, a recent
study has demonstrated that 4DST but not FLT can be
transported via the nucleoside transporters [15]. The
active transport may cause higher uptake of 11C-4DST
than 18F-FLT through the intact BBB in the normal
brain though the amount of 11C-4DST transport is
small.
In the present study, we examined 20 patients with
various grades of gliomas and a mixture of primary and
recurrent cases. There are critical limitations in the
present study. Firstly, the total number of gliomas en-
rolled in this study was small for evaluating the useful-
ness of this new tracer, especially low-grade glioma.
Secondary, primary, and recurrent cases should be sep-
arated when evaluating the usefulness of a BBB-dependent
PET tracer, such as 11C-4DST and 18F-FLT. Recently, our
research group has demonstrated that 18F-FLT PET is less
useful for evaluating tumor malignancy and cell prolifera-
tion in recurrent gliomas compared with newly diagnosed
gliomas [17]. In the present study, no significant differ-
ences in the T/N ratio of 18F-FLT were noted among dif-
ferent glioma grades. This finding is not in accordance
with the findings of our previous [4] and recent [17] stud-
ies in newly diagnosed gliomas. Moreover, there is asignificant correlation between the 18F-FLT uptake and
the Ki-67 labeling index, but the correlation coefficient
(r = 0.50) was lower compared with the findings of our
previous (r = 0.89) [4] and recent (r = 0.81) [17] studies in
newly diagnosed gliomas. These discrepancies might be
due to the small number of patients and mixture of pri-
mary and recurrent cases. Radiotherapy used as an ad-
juvant treatment for malignant gliomas may cause
loosening of the endothelial tight junctions, vascular
leakage, or endothelial cell death and thus can increase
vascular permeability not only in the BBB but also in
the blood-tumor barrier [18]. Besides increased cell
proliferation in recurrent tumors, treatment-induced
breakdown of the BBB and blood-tumor barrier might
contribute to the degree of 18F-FLT in the tumor. This
may also be the case in 11C-4DST.
Although the short physical half-life of 11C is a signifi-
cant limitation for routine clinical use, 11C-4DST has
benefits with regard to lower radiation burden and diag-
nosis using multiple tracers in 1 day. An alternative thy-
midine analogue labeled with a longer half-life isotope
that can be incorporated into DNA synthesis is applie-
d`easibly for clinical use and might provide additional
and alternative information. As 11C-4DST uptake repre-
sents the whole DNA synthesis process, 11C-4DST PET
might be superior for evaluating treatment response and
predicting prognosis compared to other tracers in pa-
tients with brain gliomas.
Conclusions
The uptake pattern and uptake value of 11C-4DST in the
tumor are similar to those of 18F-FLT, and both nucleo-
side tracers might be BBB dependent. Although no su-
periority was found in 11C-4DST over 18F-FLT in the
detection of tumors and in the evaluation of cell prolif-
eration, we consider that 11C-4DST is useful for the im-
aging of human brain gliomas with PET. Further studies
are necessary to examine the usefulness of 11C-4DST for
clinical application in evaluating treatment response and
predicting prognosis.
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